文献速递银屑病与炎症性皮肤病

阿普司特在希腊生物制剂初治中度银屑病患者中的真实世界有效性与安全性:APRAISAL研究

Effectiveness and safety of apremilast in biologic-naïve patients with moderate psoriasis treated in routine clinical practice in Greece: the APRAISAL study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2021-07-13

APRAISAL是一项52周真实世界研究,纳入生物制剂初治的中度斑块状银屑病成人患者,阿普司特在入组前≤7天内起始。 interim分析显示,第24周DLQI和PASI中位分别下降9.0和9.4分,PASI-75应答率48.0%,DLQI≤5者占63.0%,安全性与此前已知特征一致。

要点

  • 阿普司特可改善生物制剂初治中度银屑病患者的生活质量与疾病严重度。
  • 第24周PASI-75应答率48.0%,DLQI≤5者占63.0%。
  • 不良反应率21.0%,严重不良反应率2.0%。

核心结论

  • 至第24周,阿普司特改善生物制剂初治中度斑块状银屑病患者的生活质量并降低疾病严重度,安全性符合已知特征。

研究设计与样本

  • 52周真实世界研究,纳入生物制剂初治的中度银屑病成人患者(BSA 10%至<20%,或PASI 10至<20且DLQI 10至<20)。
  • 阿普司特在入组前≤7天内起始;本次 interim分析呈现前100例完成24周观察或提前退出患者的数据,采用末次观测结转法。
  • 患者于2017年4月至10月由希腊18位医院门诊皮肤科专家连续入组。

主要发现

  • 基线DLQI中位12.0、PASI中位11.7,在第6、16、24周所有基线后时间点均改善(P < 0.001);第24周中位分别下降9.0和9.4分。
  • 第24周DLQI≤5、DLQI 0或1、PASI-75应答率分别为63.0%、25.0%、48.0%。
  • 基线有甲受累者(n = 57)的NAPSI评分在所有基线后时间点下降(P < 0.001;第24周中位下降20.0分)。
  • 第24周,基线有头皮受累(n = 76)和掌跖受累(n = 29)的患者中,分别有50.0%和51.7%达到PGA 0或1(基线≥3者)或PGA 0(基线为1或2者)。
  • 不良反应率21.0%(严重2.0%)。

关键数值与推荐

  • 中度银屑病入组标准:BSA 10%至<20%,或PASI 10至<20且DLQI 10至<20。
  • 第24周PASI-75应答率48.0%,DLQI≤5者63.0%,DLQI 0或1者25.0%。
  • 第24周甲受累者NAPSI中位下降20.0分(P < 0.001)。
  • 第24周头皮和掌跖受累者PGA达标率分别为50.0%和51.7%。
  • 不良反应率21.0%,严重不良反应率2.0%。

临床怎么用

  • 对于生物制剂初治的中度斑块状银屑病成人患者,阿普司特可作为改善生活质量和疾病严重度的治疗选择。
  • 治疗24周内可关注DLQI、PASI及甲、头皮、掌跖受累的改善情况。
  • 用药期间需监测不良反应,严重不良反应发生率较低但仍需警惕。

局限性

  • 本次为interim分析,仅纳入前100例完成24周观察或提前退出的患者。
  • 采用末次观测结转法处理缺失数据。
  • 研究为真实世界单臂设计,未设对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Apremilast is an oral phosphodiesterase-4 inhibitor indicated for patients with moderate-to-severe chronic plaque psoriasis and active psoriatic arthritis. OBJECTIVES: To examine the effectiveness of apremilast on Dermatology Life Quality Index (DLQI), Psoriasis Area and Severity Index (PASI) and nail, scalp and palmoplantar involvement, when administered prior to biologics. METHODS: This 52-week real-world study included biologic-naive adults with moderate psoriasis (psoriasis-involved body surface area 10% to <20%, or PASI 10 to <20 and DLQI 10 to <20). Apremilast was initiated ≤7 days before enrolment. Data from the first 100 eligible patients who completed 24 weeks (W24) of observation (or were prematurely withdrawn) are presented in this interim analysis using the last-observation-carried-forward imputation method. RESULTS: Eligible patients (mean age: 49.9 years; 71.0% males; median disease duration: 8.0 years) were consecutively enrolled between April and October 2017, by 18 dermatology specialists practising in hospital outpatient settings in Greece. Baseline DLQI (median: 12.0) and PASI (median: 11.7) scores improved (P < 0.001) at all postbaseline timepoints (Weeks 6, 16 and 24; W24 median decreases: 9.0 and 9.4 points respectively). At W24, DLQI ≤5, DLQI 0 or 1, and PASI-75 response rates were 63.0%, 25.0% and 48.0% respectively. The Nail Psoriasis Severity Index score in patients with baseline nail involvement (n = 57) decreased at all postbaseline timepoints (P < 0.001; W24 median decrease: 20.0 points). At W24, 50.0% and 51.7% of patients with baseline scalp (n = 76) and palmoplantar (n = 29) involvement respectively achieved postbaseline Physician's Global Assessment (PGA) score of 0 or 1 if baseline score was ≥3, or 0 if baseline score was 1 or 2. The adverse drug reaction rate was 21.0% (serious: 2.0%). CONCLUSIONS: These interim results indicate that through 24 weeks, apremilast improved quality of life and reduced disease severity in biologic-naive patients with moderate plaque psoriasis, while demonstrating safety consistent with the known safety profile.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Ioannides D, Antonakopoulos N, Georgiou S, et al. Effectiveness and safety of apremilast in biologic-naïve patients with moderate psoriasis treated in routine clinical practice in Greece: the APRAISAL study. J Eur Acad Dermatol Venereol. 2021. PMID: 34036627. doi:10.1111/jdv.17392

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。